Search

Author/Creator Pegram, Mark

11. QOLP-02. PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY. (9th November 2020)

Authors:
Kumthekar, Priya; Sahebjam, Solmaz; Pegram, Mark; Ibrahim, Nuhad; Sussell, Jesse; Nicholas, Alan; Fung, Anita; Cheng, Anna; Lin, Nancy U
Journal:
Neuro-oncology
Issue:
Volume 22(2020)Supplement 2
Page Start:
ii174
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer. (October 2019)

Authors:
Pivot, Xavier; Pegram, Mark; Cortes, Javier; Lüftner, Diana; Lyman, Gary H.; Curigliano, Giuseppe; Bondarenko, Igor; Yoon, Ye Chan; Kim, Younsoo; Kim, Chul
Journal:
European journal of cancer
Issue:
Volume 120(2019)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Issue 6 (June 2017)

Authors:
Diéras, Véronique; Miles, David; Verma, Sunil; Pegram, Mark; Welslau, Manfred; Baselga, José; Krop, Ian E; Blackwell, Kim; Hoersch, Silke; Xu, Jin; Green, Marjorie; Gianni, Luca
Journal:
Lancet oncology
Issue:
Volume 18:Issue 6(2017:Jun.)
Page Start:
732
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗